Poseida Therapeutics Stock Total Debt

PSTX Stock

USD 9.31 0.02 0.21%

Poseida Therapeutics fundamentals help investors to digest information that contributes to Poseida Therapeutics' financial success or failures. It also enables traders to predict the movement of Poseida Stock. The fundamental analysis module provides a way to measure Poseida Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poseida Therapeutics stock.

Total Current Liabilities Other Current Liab

Total Debt To Capitalization is likely to rise to 0.40 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Poseida Therapeutics Company Total Debt Analysis

Poseida Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Poseida Therapeutics Total Debt

85.42 M

Most of Poseida Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poseida Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Poseida Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Poseida Therapeutics is extremely important. It helps to project a fair market value of Poseida Stock properly, considering its historical fundamentals such as Total Debt. Since Poseida Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Poseida Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Poseida Therapeutics' interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Good Will	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Deferred Long Term Liab	Capital Stock	Short Term Investments	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.83	0.2	0.61	0.83	0.84	0.72	0.85	0.94	0.69	0.13	0.72	-0.53	0.13	0.95	0.51	0.82	0.81	-0.57	0.71	0.88	0.79	0.61	0.65
Retained Earnings	-0.83		-0.52	-0.75	-0.85	-0.93	-0.8	-0.88	-0.7	-0.82	-0.07	-0.93	0.68	-0.58	-0.76	-0.78	-0.82	-0.84	0.84	-0.9	-0.94	-0.69	-0.79	-0.84
Accounts Payable	0.2	-0.52		0.05	0.4	0.4	0.79	0.43	0.19	0.17	-0.7	0.4	-0.18	0.53	0.23	0.6	0.37	0.6	-0.61	0.32	0.35	-0.16	0.12	0.21
Net Receivables	0.61	-0.75	0.05		0.56	0.79	0.33	0.56	0.45	0.7	0.53	0.84	-0.55	0.36	0.53	0.44	0.49	0.46	-0.45	0.9	0.83	0.68	0.98	0.94
Total Current Assets	0.83	-0.85	0.4	0.56		0.91	0.82	1.0	0.86	0.81	-0.13	0.87	-0.3	0.56	0.9	0.82	0.99	0.92	-0.82	0.6	0.88	0.81	0.6	0.58
Common Stock	0.84	-0.93	0.4	0.79	0.91		0.79	0.91	0.8	0.86	0.06	0.96	-0.42	0.49	0.86	0.8	0.86	0.84	-0.78	0.8	0.99	0.77	0.85	0.84
Property Plant Equipment	0.72	-0.8	0.79	0.33	0.82	0.79		0.83	0.75	0.52	-0.51	0.69	-0.25	0.42	0.77	0.74	0.8	0.91	-0.74	0.53	0.75	0.38	0.4	0.46
Total Assets	0.85	-0.88	0.43	0.56	1.0	0.91	0.83		0.86	0.81	-0.12	0.87	-0.34	0.55	0.9	0.82	0.99	0.93	-0.83	0.63	0.89	0.8	0.6	0.6
Total Stockholder Equity	0.94	-0.7	0.19	0.45	0.86	0.8	0.75	0.86		0.59	-0.08	0.64	-0.21	0.06	0.99	0.52	0.86	0.85	-0.52	0.51	0.8	0.76	0.47	0.46
Current Deferred Revenue	0.69	-0.82	0.17	0.7	0.81	0.86	0.52	0.81	0.59		0.31	0.89	-0.5	0.63	0.66	0.83	0.78	0.61	-0.83	0.67	0.84	0.86	0.78	0.79
Net Debt	0.13	-0.07	-0.7	0.53	-0.13	0.06	-0.51	-0.12	-0.08	0.31		0.14	-0.49	-0.11	-0.05	-0.21	-0.13	-0.32	0.14	0.37	0.14	0.43	0.46	0.44
Long Term Debt	0.72	-0.93	0.4	0.84	0.87	0.96	0.69	0.87	0.64	0.89	0.14		-0.47	0.66	0.72	0.84	0.82	0.77	-0.83	0.84	0.95	0.75	0.89	0.87
Good Will	-0.53	0.68	-0.18	-0.55	-0.3	-0.42	-0.25	-0.34	-0.21	-0.5	-0.49	-0.47		-0.32	-0.26	-0.27	-0.29	-0.28	0.44	-0.78	-0.51	-0.4	-0.52	-0.66
Total Liab	0.13	-0.58	0.53	0.36	0.56	0.49	0.42	0.55	0.06	0.63	-0.11	0.66	-0.32		0.15	0.77	0.55	0.43	-0.79	0.4	0.43	0.34	0.42	0.43
Net Invested Capital	0.95	-0.76	0.23	0.53	0.9	0.86	0.77	0.9	0.99	0.66	-0.05	0.72	-0.26	0.15		0.59	0.89	0.88	-0.59	0.58	0.86	0.79	0.55	0.54
Short Long Term Debt	0.51	-0.78	0.6	0.44	0.82	0.8	0.74	0.82	0.52	0.83	-0.21	0.84	-0.27	0.77	0.59		0.79	0.76	-0.97	0.51	0.73	0.56	0.54	0.55
Net Working Capital	0.82	-0.82	0.37	0.49	0.99	0.86	0.8	0.99	0.86	0.78	-0.13	0.82	-0.29	0.55	0.89	0.79		0.92	-0.81	0.55	0.83	0.81	0.53	0.51
Short Term Debt	0.81	-0.84	0.6	0.46	0.92	0.84	0.91	0.93	0.85	0.61	-0.32	0.77	-0.28	0.43	0.88	0.76	0.92		-0.79	0.61	0.82	0.6	0.47	0.48
Intangible Assets	-0.57	0.84	-0.61	-0.45	-0.82	-0.78	-0.74	-0.83	-0.52	-0.83	0.14	-0.83	0.44	-0.79	-0.59	-0.97	-0.81	-0.79		-0.6	-0.73	-0.58	-0.53	-0.56
Deferred Long Term Liab	0.71	-0.9	0.32	0.9	0.6	0.8	0.53	0.63	0.51	0.67	0.37	0.84	-0.78	0.4	0.58	0.51	0.55	0.61	-0.6		0.86	0.59	0.88	0.92
Capital Stock	0.88	-0.94	0.35	0.83	0.88	0.99	0.75	0.89	0.8	0.84	0.14	0.95	-0.51	0.43	0.86	0.73	0.83	0.82	-0.73	0.86		0.79	0.87	0.88
Short Term Investments	0.79	-0.69	-0.16	0.68	0.81	0.77	0.38	0.8	0.76	0.86	0.43	0.75	-0.4	0.34	0.79	0.56	0.81	0.6	-0.58	0.59	0.79		0.68	0.63
Long Term Debt Total	0.61	-0.79	0.12	0.98	0.6	0.85	0.4	0.6	0.47	0.78	0.46	0.89	-0.52	0.42	0.55	0.54	0.53	0.47	-0.53	0.88	0.87	0.68		0.97
Capital Surpluse	0.65	-0.84	0.21	0.94	0.58	0.84	0.46	0.6	0.46	0.79	0.44	0.87	-0.66	0.43	0.54	0.55	0.51	0.48	-0.56	0.92	0.88	0.63	0.97

Click cells to compare fundamentals

Poseida Total Debt Historical Pattern

Today, most investors in Poseida Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Poseida Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Poseida Therapeutics total debt as a starting point in their analysis.

Poseida Therapeutics Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Poseida Therapeutics

Short Long Term Debt Total Over Time

Poseida Short Long Term Debt Total

Short Long Term Debt Total

55.41 Million

At this time, Poseida Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year.

Based on the latest financial disclosure, Poseida Therapeutics has a Total Debt of 85.42 M. This is 96.89% lower than that of the Biotechnology sector and 73.7% lower than that of the Health Care industry. The total debt for all United States stocks is 98.39% higher than that of the company.

Poseida Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poseida Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics of similar companies.

Poseida Therapeutics is currently under evaluation in total debt category among its peers.

Poseida Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Poseida Therapeutics from analyzing Poseida Therapeutics' financial statements. These drivers represent accounts that assess Poseida Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Poseida Therapeutics' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		551.3M	370.2M	278.3M	388.5M	344.0M	545.8M

Poseida Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Poseida Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Poseida Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Poseida Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Poseida Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Poseida Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Poseida Therapeutics' value.

		Shares
Jacobs Levy Equity Management, Inc.	2024-09-30	811.5 K
Morgan Stanley - Brokerage Accounts	2024-06-30	726.6 K
Millennium Management Llc	2024-06-30	643 K
Charles Schwab Investment Management Inc	2024-09-30	567.1 K
Northern Trust Corp	2024-09-30	565.4 K
Dimensional Fund Advisors, Inc.	2024-09-30	563.1 K
Goldman Sachs Group Inc	2024-06-30	501.9 K
Nuveen Asset Management, Llc	2024-06-30	402.9 K
Wellington Management Company Llp	2024-06-30	387.3 K
Fmr Inc	2024-09-30	14.6 M
Pentwater Capital Management Lp	2024-09-30	6 M

Poseida Fundamentals

	Return On Equity	-0.58
	Return On Asset	-0.13
	Profit Margin	(0.40) %
	Operating Margin	0.28 %
	Current Valuation	759.29 M
	Shares Outstanding	97.47 M
	Shares Owned By Insiders	27.64 %
	Shares Owned By Institutions	58.48 %
	Number Of Shares Shorted	4.61 M
	Price To Earning	214.00 X
	Price To Book	10.40 X
	Price To Sales	6.03 X
	Revenue	64.7 M
	Gross Profit	(22.41 M)
	EBITDA	(109.04 M)
	Net Income	(123.43 M)
	Cash And Equivalents	142.56 M
	Cash Per Share	1.66 X
	Total Debt	85.42 M
	Debt To Equity	1.39 %
	Current Ratio	3.69 X
	Book Value Per Share	0.90 X
	Cash Flow From Operations	(92.17 M)
	Short Ratio	8.30 X
	Earnings Per Share	(0.63) X
	Price To Earnings To Growth	(0.63) X
	Target Price	9.5
	Number Of Employees	350
	Beta	0.54
	Market Capitalization	909.36 M
	Total Asset	273.88 M
	Retained Earnings	(594.29 M)
	Working Capital	155.16 M
	Current Asset	10.59 M
	Current Liabilities	5.1 M
	Net Asset	273.88 M

About Poseida Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Poseida Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poseida Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poseida Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC